RZV

AcronymDefinition
RZVRhizidiomyces Virus
References in periodicals archive ?
Under the contract Shoden consolidated RZV's open and mainframe storage backups onto a single platform where it also replaced tapes with disks.
The system has also allowed RZV to enhance its Disaster Recovery processes through the move from tape to disk, while curbing costs and floor space needs.
CDC and FDA investigators conducted descriptive analyses of reports to VAERS involving RZV for the period October 20, 2017-June 30, 2018.
During the analytic period, VAERS received 4,381 RZV reports (Table 1), for a rate of 136 reports per 100,000 doses distributed; among these, 130 (3.0%) were classified as serious (four serious reports per 100,000 doses distributed).
Seven confirmed deaths after receipt of RZV were reported.
RZV and ZVL differ with regard to vaccine type, dose, and schedule; ACIP recommendation; route of administration; and storage requirements (Table).
During the first 4 months of RZV monitoring (October 20, 2017-February 20, 2018), the Vaccine Adverse Event Reporting System (VAERS) (4) received 155 reports involving RZV, 13 (8%) of which documented an administration error, including some reports documenting more than one error.
Although data from passive reporting to VAERS and inquiries submitted to CDC limit the ability to draw conclusions regarding the cause of the administration errors, early monitoring indicates that vaccine providers might confuse administration procedures and storage requirements of the older ZVL and the newer RZV. Failure to reconstitute the vaccine and administration of only one component of RZV also appears to be occurring, similar to errors observed for other vaccines that require mixing (5).
ACIP considered use of RZV, as well as existing recommendations, to develop vaccination policy which would be safe and reduce disease burden.
From March 2015 to October 2017, the ACIP Herpes Zoster Vaccines Work Group (Work Group; see acknowledgments for members and their affiliations) participated in monthly or bimonthly teleconferences to review herpes zoster epidemiology and the evidence for the efficacy, safety, and programmatic factors of RZV and ZVL.